Transcript depletion using small interfering RNA (siRNA) technology represents a potentially valuable technique for the treatment of cancer. However, delivering therapeutic quantities of siRNA into solid tumors by chemical transfection is not feasible, whereas viral vectors efficiently transduce many human tumor cell lines. Yet producing sufficient quantities of viral vectors that elicit acute and selective cytotoxicity remains a major obstacle for preclinical and clinical trials. Using the invertebrate Spodoptera frugiperda (Sf9) cell line, we were able to produce high titer stocks of cytotoxic recombinant adeno-associated virus (rAAV) that express short hairpin RNA (shRNA) and that efficiently deplete Hec1 (highly expressed in cancer 1), or Kntc2 (kinetochore-associated protein 2), a kinetochore protein directly involved in kinetochore microtubule interactions, chromosome congression and spindle checkpoint signaling. Depletion of Hec1 protein results in persistent spindle checkpoint activation followed by cell death. Because Hec1 expression and activity are only present in mitotic cells, non-dividing cells were not affected by rAAV treatment. On the basis of the results of screening 56 human tumor cell lines with three different serotype vectors, we used a tumor xenograft model to test the effects in vivo. The effects of the shHec1 vector were evident in sectioned and stained tumors. The experiments with rAAV-shRNA vectors demonstrate the utility of producing vectors in invertebrate cells to obtain sufficient concentrations and quantities for solid tumor therapy. This addresses an important requirement for cancer gene therapy, to produce cytotoxic vectors in sufficient quantities and concentrations to enable quantitative transduction and selective killing of solid tumor cells.
Introduction
RNA interference (RNAi) is the cellular process in which a short double-stranded RNA (dsRNA) causes degradation of the complementary mRNA. [1] [2] [3] [4] [5] [6] This results in potent, specific gene silencing. Since it was discovered in 1998, small interfering RNA (siRNA) has rapidly developed as a major research technique for depleting specific transcripts in mammalian cells. [7] [8] [9] [10] [11] [12] Compared to antisense and other mRNA depletion techniques, siRNA more rapidly and effectively creates loss-of-function phenotypes. As such, this technique has potential for therapeutic applications. However, delivering sufficient quantities of siRNA in vivo remains perhaps the biggest problem for developing siRNA therapeutic applications. Short hairpin RNAs (shRNAs), expressed from a DNA template that forms an intramolecular duplex RNA, were then investigated as an alternative to siRNA in shutting off gene expression, and it has been shown that shRNA silences genes as effectively as siRNA in human cells. 13, 14 Depending on the vector system, the vector DNA either stably integrates into the cellular genome, for example lentivirus vectors, or remains episomal, for example recombinant adeno-associated virus (rAAV). The shRNA vectors have proven effective in vitro, and have been widely used to probe gene function in a variety of experimental applications. Further, shRNA expression vectors have been used successfully to downregulate gene expression in vivo. [15] [16] [17] [18] Hec1 (highly expressed in cancer 1), or Kntc2 (kinetochore-associated protein 2, NM006101.1), is a vital component of the kinetochore outer plate. Hec1 is required for proper attachment of microtubules by the kinetochore. [19] [20] [21] [22] [23] [24] It is a subunit of the heterotetrameric Ndc80 complex consisting of Hec1, Nuf2, Spc24, and Spc25, of which there are approximately 1000 copies per kinetochore. 25 The Ndc80 complex is required for proper kinetochore assembly, and kinetochores fail to bind productively microtubules after siRNA knockdown of any one of the subunits. These cells arrest in mitosis for 4-8 h and then die. 23 Because of the specific induction of cell death in dividing cells, Hec1 was proposed for a cancer therapy target. 21, 26, 27 Recently, Gurzov and Izquierdo 28 described the construction of Hec1-shRNA in retroviruses and adenoviruses for cancer gene therapy.
Our laboratory has developed a novel process for generating large quantities of recombinant AAV in suspension culture of lepidopteran Spodoptera frugiperda (Sf) insect cells. Using the Sf 9 cell line, we produced rAAV-shHec1 in high titers, as much as 10 13 viral genome per liter of cultured insect cells. Using rAAV-shHec1 vector that we produced in Sf 9 cells, we observed potent Hec1 gene silencing and dose-dependent selective killing of dividing cells.
Vectors based on adeno-associated viruses (AAV) possess several attractive features for gene transfer applications, including the ability of the vector DNA to persist in an episomal form, resulting in lasting gene expression. 29 The rAAV nanoparticle is a non-replicating virus vector derived from the human and primate dependovirus genus Parvoviridae. Physically, the particles are non-enveloped, icosahedra with a diameter of approximately 20-25 nm. Cell surface virus receptors, which vary among the 12 characterized serotypes, partially determine the cell types that are sensitive to virus or vector infection. AAV2 capsids utilize heparan sulfate proteoglycans (HSPG) as a primary receptor 30 and fibroblast growth factor receptor and integrin a v b 5 as coreceptors. 31 Other AAV serotypes appear to use different attachment receptors, such as a-2-3 O-linked sialic acid and N-linked sialic acid for AAV4 and AAV5, respectively 32 and laminin appears to have involvement in binding AAV serotypes 8, 2, 3 and 9 capsids. 33 Matching the target cell with the most efficient vector serotype provides greater biological potency of the vector for the specific application. Previous studies demonstrated that AAV2 is the most effective serotype for transducing a number of tumor cell lines including certain cervical, breast and skin cancers. 34 However, much variability exists in the efficiency with which each AAV serotype transduces a particular tumor cell line. An understanding of what serotypes are effective in transducing specific cancer cell types derived from different tissues, and how well the AAV serotypes transduce them would greatly benefit efforts to use AAV for cancer therapy applications. Therefore, the current study was carried out to create a profile of the transduction efficiency of AAV serotypes 1, 2 and 5 on 56 human tumor cell lines derived from nine different organs.
On the basis of these results of tumor cells, screening two of the most efficiently transduced glioma cell lines, U251 and SF-539, were used to test the rAAV-shHec1 effect in tumor cells. We observed tumor cell death after rAAV-shHec1 treatment in either cell lines. To study further the specificity of the rAAV-shHec1 in targeting only mitotically active cells, in vitro studies were conducted using primary mouse neurons and contactinhibited human embryonic kidney (HEK) 293 cells. These mitotically inactive cells showed no effects caused by high titer rAAV-shHec1 vector transduction. Importantly, in nude mouse xenografts U251 glioma tumor model, tumors injected with rAAV-shHec1 were highly fibrotic and had lower cell density than either control sets of tumors. These studies demonstrate that rAAV shHec1 vector selectively kills mitotically active cells such as those found in a growing tumor. Using Spodoptera frugiperda (Sf9) cells to produce large quantities of cytostatic or cytotoxic vector may provide a basis for treating patients with unresectable solid tumors.
Results

Hec1 siRNA oligonucleotide and rAAV Hec1 shRNAi vector
A set of four siRNA duplex oligonucleotides were synthesized complementary to different regions of the human Hec1 cDNA (Figure 1a) . The levels of endogenous Hec1 in HEK293 cells were assessed by Western blot after transient transfection with each of the four siRNA oligonucleotides. On the basis of these amounts of Hec1 protein detected by Western blots, the siHec1(1) and siHec1(4) oligonucleotides had the greatest effects, whereas siHec1(2) caused moderate depletion and siHec1(3) appeared to have no effect on Hec1 level relative to untreated controls (data not shown). On the basis of these results, shRNA expressing AAV vectors, rAAV-shHec1(1), rAAV-shHec1(4), and rAAVshHec1(4E), a modified version of siHec1(4), were produced ( Figure 1b) . Each shHec1 AAV vector contains an independently regulated cassette for expression of humanized Renilla green fluorescent protein (hrGFP) used as a transduction marker. HEK293 cells treated with rAAV-shHec1(4) and rAAV-shHec1(4E) displayed moderate to severe phenotypic effects, for example, reduced cell number and density, and changed in cell morphology. It appeared that rAAV-shHec1(4E) was the most effective shHec1 AAV vector ( Figure 2 ).
AAV Hec1 shRNAi vector induced cell growth arrest
The rAAV-shHec1(4E) vector which induced the most potent effect on cellular morphology was further characterized. A time course was performed and at 16 h post-transduction with rAAV shuttle vector, more than 90% of treated HEK293 cells were hrGFP-positive and appeared morphologically normal (Figure 3a and b, respectively). At this early time point, the rAAVshHec1(4E)-treated cells, approximately 20% of HEK293 cells appeared circular and reflective under phasecontrast microscopy ( Figure 3c ) and 100% of the round cells were hrGFP-positive (Figure 3d ). At 40 h posttransduction, essentially all the rAAV-shHec1(4E)-treated cells were rounded (Figure 3g ). The round, reflective cells accumulate over time and indicates a block in cell growth. This observation is consistent with Hec1 protein depletion resulting in spindle checkpoint maintenance and cell division arrest. Regardless of treatment, all the cells are hrGFP-positive (Figure 3f and h), indicating transduction with the respective vector. After 112 h, the cells exposed to rAAV shuttle approached confluence and were hrGFP-positive (Figure 3i and j) , whereas the few cells remaining in the rAAV-shHec1(4E)-treated wells were probably non-viable (Figure 3k and l) . The same morphology changes were observed in other cell AAV-mediated shRNA depletion of Hec1 L Li et al lines, such as COS1, after transduction with rAAVshHec1(4E) vector.
Hec1 siRNA has also been shown previously to prevent chromosome congression and disrupt the mitotic spindle. Similar phenotypes have been reported for knockdown of the three other hNdc80 complex members. HeLa cells were also infected with either rAAVshHec1(4E) or shuttle vector and whole-cell lysates collected after 48 h. Western-blot analysis comparing rAAV-shHec1(4E) lysates to serial dilutions of uninfected HeLa cells showed Hec1 protein level reduced approximately 90% (Figure 3m ). Shuttle vector infected cells showed no decrease in Hec1. At 48 h post-infection, cells were also fixed and processed for immunofluorescence microscopy. Hec1 protein was no longer detected at kinetochores of rAAV-shHec1(4E)-infected cells, but was present in shuttle vector infected cells (Figure 3n ). Imaging of mitotic spindles showed metaphase chromosome congression defects in rAAV-shHec1(4E)-infected cells (Figure 3o ). Only 31.3% of mitotic rAAVshHec1(4E)-infected HeLa cells were able to align a normal metaphase plate. Shuttle vector infected cells were able to align chromosomes at the metaphase plate in 71.3% of mitotic cells, consistent with the amount seen in uninfected HeLa cells (unpublished observations). These data show that Hec1 depletion by rAAV-shHec1 vector in HeLa cells induced mitotic spindle morphology anomalies preventing mitotic progression.
Cell death induced in rAAV-shHec1-treated cells
Using DNA content as an indicator of cell-cycle phase, the effects of rAAV-shHec1(4E) vector treatment were a siHec1 (3) siHec1 (4) rAAV-shuttle HEK293 cell con.
rAAV-shHec1(4E) rAAV-shHec1 (1) rAAV-shHec1(4) Figure 2 Treatment with rAAV-shHec1 affected cell growth and morphology. HEK293 cells were transduced with AAV serotype 2 vector carrying shRNA targeting kinetochore Hec1 protein (MOI ¼ 5000). Cells are shown 6 days post-transduction. Of the three vectors, rAAVshHec1(4E) had the strongest effect, rAAV-shHec1(4) had less effect and rAAV-shHec(1) had little or no effect on cell growth and morphology. 5 with rAAV-shHec1(4E). These data indicate that the cells do not proceed through mitosis and eventually die.
Giemsa dye staining was used to determine whether cells treated with rAAV-shHec1(4E) recover from the Hec1 depletion and resume growth. To determine the range that rAAV-shHec1(4E) induces cell death, serially diluted vectors to provide a range of 10 particles per cell, no cells survived to colonize the wells after 7 days. In contrast, no difference in cell survival at any concentration was observed with rAAV2-shuttletreated HEK293 cells. Thus, the lethality of the vector is dependent on the number of AAV-shHec1(4E) particles applied.
Human tumor cell lines susceptibility to AAV
A fundamental requirement for AAV-mediated gene transfer for cancer therapy is efficient transduction of the tumor cells. Although AAV vectors are considered to have broad tropism, transduction efficiency varies with cell type and vector serotype. To determine the optimal combination of tumor type and AAV serotype, we performed a matrix analysis of three diverse serotypes (AAV1, AAV2 and AAV5) in 56 human tumor cell lines. These AAV vector genomes (vgs) also contain an AAV-mediated shRNA depletion of Hec1 L Li et al expression cassette for eGFP, which is used as a transduction reporter. The eGFP fluoresence, which is similar to hrGFP, was observed by fluorescence microscopy from day 1 to day 7 after transduction. The results of eGFP expression level for AAV1-eGFP, AAV2-eGFP and AAV5-eGFP were summarized in Table 1 (columns  1, 2 and 3) . Of the three serotypes tested, we found that rAAV2-eGFP generally had the highest transduction rate and earliest eGFP onset. Furthermore, analyzed quantitatively, the results showed that 33 out of 55 cell lines had 470% cells transduced with rAAV5-eGFP ( Table 1 , column 4). However, the transgene expression levels in the 56 human tumor cell lines were different. Melanoma and glioma tumor cells achieve the highest eGFP intensity, lung and renal attained moderate eGFP fluorescent levels, whereas most tumors from ovarian, colon, breast, prostate and blood (leukemia) were poorly transduced with AAV (Table 1, column 5). As an example, U251 and SF-295 (highly transduced) and DU-145 (poorly transduced) cell lines are shown ( Figure   5 ). These results suggest that AAV vector represents an efficient gene delivery vector for many different type cancers, especially central nervous system (CNS) tumors and melanoma. In summary, the order of rAAV affinity for human tumor are cells from CNS, melanoma 4 lung 4 renal, breast 4 colon 4 leukemia, prostate, ovarian.
rAAV-shHec1 depletion Hec1 protein resulted in U251 and SF-539 tumor cell death Two CNS tumor cell lines, U251 and SF-539, were among the most efficiently transduced tumor cell lines using eGFP expression vectors. The effects of rAAV-shHec1 were then evaluated on those cell lines. To determine the most effective shRNA for Hec1 depletion in U251 and SF-539 glioma cell line, Western blots were used to detect the endogenous Hec1 protein levels following treatment with three different shHec1 expression vectors. A marked reduction in the endogenous Hec1 protein levels in both cell lines 24 h after treatment with rAAV- Not surprisingly, the pronounced Hec1 depletion lasted several days (Figure 6b ). At 2, 3 and 4 days posttransduction, no Hec1 signal was detected in lysates of cells treated with rAAV-shHec1(4E); however, treatment with the rAAV shuttle had little or no effect on Hec1 protein levels. These results indicate that rAAV-shHec1 induced persistent Hec1 protein depletion in AAVsusceptible tumor cell lines. To determine whether Hec1 protein depletion in human tumor cell lines caused the same effects on cell viability as observed in HEK293 or HeLa cell lines, U251 cells were transduced with rAAV-shHec1(4E). At 40 h post-transduction, X95% of U251 cells clearly displayed anomalous rounded morphology phenotype and were also hrGFP-positive, whereas U251 cells transduced with the control rAAV shuttle were hrGFP-positive but appeared morphologically normal (Figure 7a ). Similar to HEK293 cells, Giemsa staining showed no U251 cell growth on the cell culture plate 14 days after transduction with rAAV-shHec1(4E) (multiplicity of infection (MOI) ¼ 2 Â 10 4 ) (Figure 7b ). This result indicates that no cells recovered from the rAAV-shHec1(4E) treatment. At a lower dose of rAAV-shHec1(4E) (MOI ¼ 4 Â 10 3 ), few cells recovered from AAV-shHec1(4E) infection appearing as stained foci in the wells (Figure 7b ).
rAAV-shHec1 vector causes cell death in mitotic, but not non-dividing cells
Although Hec1 gene expression is cell-cycle regulated and Hec1 protein has no known functions in nondividing cells, we tested whether rAAV-shHec1(4E) expression affected non-dividing cells by possible 'offtarget' effects. Two models were used, HEK293 cells plated at high and low densities were transduced with either rAAV shuttle or rAAV-shHec1(4E). The low density (8 Â 10 4 cells/well in 24-well plate) cells transduced with rAAV-shuttle (MOI ¼ 7500) grew to near confluence, but the rAAV-shHec1(4E) (MOI ¼ 7500) transduced cells did not grow and contained many dead cells (Figure 8a , right panels). However, cells seeded at high density (4 Â 10 5 cells/well in 24-well plate) and transduced with either vector appeared similar after 6 days ( Figure 8a , left panels). We then used mouse brain primary cerebella granule neurons (CGNS) as a second model to test the effects of rAAV-shHec1(4E) on nondividing primary cells. CGNS cells can be maintained in vitro for 4 weeks with no mitotic activity. Twenty-four hours after seeding CGNS cells on poly-lysine-coated cell culture plates, rAAV shuttle (MOI range from 4 to 3.2 Â 10 5 ) or rAAV-shHec1(4E) vector (MOI range from 4 to 1.7 Â 10 5 ) was applied to the CGNS cells. Both AAV serotypes 1 and 2 capsids for each of the vgs were used in these non-dividing CGNS cell experiments with indistinguishable outcomes. After 7 days, the rAAV shuttle as well as rAAV-shHec1(4E)-transduced cells appeared normal (Figure 8b ). At 28 days post-transduction, no effects were observed with either rAAVshHec1(4E)-or rAAV-shuttle-treated cells. Thus, rAAV-shHec1(4E) transduction elicited a phenotypic effect only in the mitotically active cells.
In vivo effect of intratumoral injection of AAV-shHec1 in xenograft solid tumor model
To assess antitumor activity by intratumoral injection of rAAV-shHec1 vector in vivo, U251 glioma xenograft mouse model was used. Solid tumors were established in immune incompetent, Hsd:athymic nude-Foxn1nu, mice by subcutaneous injection of U251 glioma tumor cells (4 Â 10 6 ). As both serotypes 1 and 2 shHec1 AAV vectors had almost equally strong effect on depletion of Hec1 protein and cell killing in vitro, we used serotype 1 shHec1 vector in our in vivo experiments because it has been reported that serotype 1 rAAV vector (rAAV1) had better distribution and transduction in the CNS. 35 Once the solid tumor became palpable in the flanks of the animal, 1.1 Â 10 9 vg of serotype 1 rAAV-shHec1(4E) vector (on right side flank) or rAAV shuttle vector (on left side flank) in total 20 ml was carefully injected into the approximate center of the tumor mass (15 mice of each group). To increase the effects of vector treatment, three weekly injections were given. Three weeks after the first intratumoral injection treatment, tumor masses were removed from the athymic mice after euthanasia followed by fluorescence stereomicroscope observation of the section. The intratumoral hrGFP expression was detected 3 weeks after the final intratumoral injection of rAAV vector (Figure 9 ). Fluorescent microscropy of the dissected tumor shows that hrGFP expression is most intense in the center of xenograft U251 solid tumor model and permeated the entire tumor mass. All 30 of Tumor masses 3 weeks after intratumoral injection were sectioned and stained for histopathology analysis. In the xenograft U251 cell line tumors, the histological characteristics resemble human gliomas. The tumor histology showed the following characteristics: (1) a high mitotic index; (2) large necrotic foci; (3) intratumoral hemorrhage; and (4) inflammation (Figure 10a and b) . In the rAAV-shHec1(4E)-treated group, several larger coagulative necrotic foci, presumably ischemic, are evident in the center of tumors. Near the necrotic areas, a thin layer of reactive cells had developed along the demarcation line with the tumor, but there was no granulation tissue. In contrast, the necrotic areas usually contained more inflammatory cells in the rAAV shuttle or no treatment control groups (Figure 10b ). The cellular growth pattern of tumor appeared differently in rAAVshHec1-treated group to those in controls. The cords that contained central vessels were seen in both groups; however, the tumor cell density in rAAV-shHec1-treated group was lower than controls (Figure 10a and c) . Occasionally, in rAAV-shHec1-treated group, the tumor cells were of smaller sizes and the tumor had formed multiple vacuoles between the cords. Masson stain (Figure 10c ) showed less tumor cell density (pink) and more connective tissue (blue) in rAAV-shHec1-treated group than controls. Although no significant tumor growth reduction in the xenograft model was observed, the histopathology results demonstrate that intratumoral injection AAV-shHec1 caused an obvious effect in xenograft U251 solid tumor model.
AAV-
mediated shRNA depletion of Hec1 L Li et al
Discussion
RNAi provides a powerful mechanism to create rapidly and effectively loss-of-function phenotypes by efficiently depleting a specific set of transcripts. Therapies based on RNAi strategies are currently being developed. Anticancer gene therapy using siRNA have targeted various proteins involved in either cell-cycle regulation, or pathways sensitizing transformed cells to apoptosis, such as polo-kinase 1, 36,37 survivin 38,39 and A1 receptor. 40 In this paper, our strategy to kill selectively tumor cells exploits the most fundamental basis of neoplastic transformation and malignancy, which is the requirement for mitosis. rAAV-shHec1 depletion of Hec1 activates the mitotic spindle checkpoint and eventually induces cell death efficiently. In this study, we produced rAAV-shHec1 vector in Sf 9 insect cells. This system provides us the ability to produce therapeutic quantities of vector in a baculovirus insect cell expression system. Because Sf 9 cells grown in suspension can be infected with recombinant baculoviruses to produce rAAV, the amount of rAAV that can be produced is limited only by the size of the vessel. 4 rAAV-shHec1(4E) particles per cell is sufficient to induce U251 cell death (Figure 4) . For discussion purposes, we estimate that the solid tumors cell density is 10 9 tumor cells per cm 3 . Therefore, 10 13 AAV particles are required to achieve a lethal dose of 10 4 AAV particles per cell. Using insect cells to produce high titer therapeutic quantities of rAAV-shHec1 vector as a potential cancer gene therapy drug offers the promise for treatment of rapidly growing solid tumors. Another potential important advantage of this AAV production system is its ability to produce cytotoxic vectors, which may not be feasible to produce in mammalian cells because the toxic gene products are expressed during vector production, thereby limiting vector yield. The interspecific genetic differences between mammalian and lepidopteran cells might restrict or even prevent this undesirable effect. This advantage may have wide ranging benefits for producing rAAV that target other vital gene products.
As a gene delivery tool, AAV vectors are powerful and extremely versatile. Studied extensively for over a decade, AAV biology is well understood with the vector having been tested and used successfully in a large range of cell types and tissues. However, owing to the multiplicity of factors involved in AAV transduction efficiency, it is difficult to predict which AAV serotypes will efficiently transduce a certain tumor cell type. Our analysis of AAV susceptibility in 56 human tumor cell lines using three diverse serotype AAV vectors (AAV1, AAV2 and AAV5) provides a basis for optimizing the match between serotype and tumor cell type. In general, the melanoma and the CNS tumor cell lines were readily transduced with AAV. Some of the tumor cell lines had much stronger (several fold) GFP expression compared to the highly susceptible HEK293 cell lines. Our results showed the highly transduced human tumor cell lines were derived from various tissue types including breast (e.g. BT-549 and HS 578T; blood (e.g. SR); melanoma (e.g. SK-MEL2 and UACC-257); lung (e.g. NCI-H226 and EKVX); and CNS (e.g. SNB-75 and SF-295). Tumor cell lines derived from colon, prostate and ovarian cancers were generally poorly transduced.
Among the three serotypes of AAV we tested, the order of transduction efficiency and onset of transgene expression was rAAV24rAAV14rAAV5. Although the slow time course of rAAV5-mediated gene expression is not a desirable characteristic at day 1, by day 6, the majority of the tumor cell lines transduced with rAAV showed eGFP expression (Table 1) . Although relative higher MOI is needed for rAAV1 to produce the same transgene expression intensity as rAAV2, our result revealed that both serotypes 1 and 2 rAAV-shHec1 vectors effectively depleted Hec1, which cause growth arrest and cell death in human glioma U251 and SF 539 cell lines. Together, our data indicated AAV vector has potential uses for cancer therapy.
The use of rAAV for solid cancer therapy depends not only on dose, that is particles per cell, but also on distribution in the tumor mass. The small diameter of the AAV capsid facilitates interstitial distribution, whereas larger virus and non-viral particles, for example adenovirus or herpes virus, do not move as well between cells. Thus, delivered intratumorally, rAAV may permeate the entire tumor volume and, if sufficient particles are infused, all tumor cells will be infected. In our glioma U251 tumor xenograft model, silencing of critical Hec1 gene product by RNAi technology via AAV vector has generated significant antiproliferative or pro-apoptotic effects in vitro and in vivo. Thus, we predict that the effect of knockdown Hec1 by siRNA can be used as a new strategy for cancer therapy. Although we examined glioma cells, rAAV-shHec1 killing of cancer cells is not limited to CNS tumors. Other solid tumors especially rapidly growing human solid tumors such as aggressive pancreatic tumor and rapid-growth lung cancer may be candidates for this application. 
Materials and methods
Identification of efficient siHec1 sequences
Cloning of shRNAs
Polymerase chain reaction (PCR)-based cloning stratagy was used to amplify the human hU6 promoter along with shRNAs targeting human Hec1. On the basis of these siRNA transfection results, three siRNA sequences were selected and cloned as shRNA. The sense and antisense strands of the stem are underlined and the loop is indicated in italics. shHec1(1) (GAAGAAAGCTACTC TAATTTTCTCTTAAGTAAAATTAGAGTAGCTTTCTTC TTTTTT); shHec1(4) (GAGTAGAACTAGAATGTGATTC TCTTAAGTAATCACATTCTAGTTCTACTCTTTTTT); sh Hec1(4E) (GAGTGGAATTAGAGTGTGGTTCTCTTAAG TAATCACATTCTAGTTCTACTCTTTTTT). Modification on sense shHec1(4E) sequence was made to increase the shRNA silencing Hec1 effect. 41 To clone the shRNA cassettes into AAV shuttle vector, oligonucleotides forward primer (28 nts) 5 0 -GTACTAGTAAGGTCGGG CAGGAAGAGGG-3 0 and reverse primer (85 nts) 5 0 -GTGGAAAGGACGAAACACCG-shHec1 (1, 4 or 4E)-GAATTCAT-3 0 were synthesized (Integrated DNA Technologies, Inc., Coralville, IA, USA) for use as PCR primers incorporating the human (h)U6 promoter along with the shRNAs. The forward primer, complementary to the hU6 promoter was used with each of three specific shRNA primers (reverse). Restriction endonuclease sites, SpeI or EcoRI, were built into the forward and reverse primers, respectively, to facilitate subsequent cloning steps. PCR (Platinum PCR SuperMix High Fidelity, Invitrogen Co.) was used to amplify the hU6 promoter from a template 15 ( Figure 1b) . The PCR products were digested by SpeI and EcoRI and inserted into pAAV.CMV.hrGFP, which is organized as follows: AAV serotype 2 inverted terminal repeat -hU6 promoter shRNA -CMV immediate early promoter -hrGFP open reading frame -simian virus 40 polyadenylation site -AAV2 inverted terminal repeat. Flanking the AAV vector DNA are sequences used for transposase-mediated AAV-mediated shRNA depletion of Hec1 L Li et al recombination into bacmid DNA. 42 Correct insertions of shRNA cassettes were confirmed by restriction mapping and DNA sequencing.
rAAV production
The high titer rAAV were produced in a lepidopteran cell line, Sf 9, derived from S. frugiperda. In this system, a set of three recombinant Autographa californica nuclear polyhedrosis viruses (AcNPV), commonly referred to as baculovirus expression vectors (BEVs) were used to introduce the cis and trans elements for rAAV production. Two different BEVs co-infecting Sf 9 cells express the structural and non-structural AAV proteins, whereas a third provides the rAAV genome. In the presence of the AAV Rep 78 protein, the rAAV genome was 'rescued' from the BEV genome, and then utilizing the AAV origins, the genome was replicated to high copy number. The linear, single-stranded DNA vector genomes are then packaged into the AAV capsids. BEVs with shRNA expression cassettes and a separate hrGFP expression cassette were used and provided to produce Hec1 silencing rAAV (details provided below). AAV serotypes 1 and 2 AAV capsid BEVs were used to produce rAAV1 and rAAV2, respectively. The details of rAAV serotype production in Sf9 cells were described previously. 42, 43 The rAAV concentrations were determined by quantitative (q) PCR and biological activities were determined by hrGFP transduction assays in HEK293 cells. Western-blot analyses using anti-capsid serum were used to determine capsid protein composition. rAAV2 produced in insect cell cultures yielded between 2 and 10 Â 10 12 vector genomes per liter of culture and the yield of the rAAV1 stock was 1-10 Â 10 11 vector genomes per liter of culture.
Processing rAAV
Small-scale insect cell cultures (p0.4 l) were processed as follows: the entire culture was subjected to three freezing-thawing cycles and then the supernatant was clarified by centrifugation at 2000 Â g for 10 min at room temperature (RT). After discarding the cell debris, a 50% solution of polyethylene glycol (PEG) 8000 is added to obtain a final concentration of 2%. The PEG/supernatant solution is agitated gently at 41C for 3-16 h. Centrifugation (5000 r.p.m. for 30 min Sorvall GSA rotor) precipitates the rAAV particles and other proteins. To purify further the vector and to separate empty capsids from vg-containing capsids, the pellet is resuspended in CsCl solution (density ¼ 1.42 g/cm 3 , with reflective index ¼ 1.372) and centrifuged in a swinging bucket rotor (Beckman SW40, Beckman Coulter, Inc., Fullerton, CA, USA) for 66-72 h at 38 000 r.p.m. at 201C. The gradients were fractionated by puncturing the tube and collecting approximately 10 Â 1 ml fractions. The densities of the fractions were determined by measuring the refractive index and samples were either stored in CsCl or dialyzed against phosphate-buffered saline (PBS) plus 2 mM MgCl 2 . Empty capsids have a lower buoyant density than vg-containing capsids. 
Immunofluorescence
HeLa cells were seeded onto poly-lysine-coated coverslips and infected as described previously. Forty-eight hours post-infection, cells were fixed in 2% paraformaldehyde/0.5% TX-100/1 Â PHEM. Cells were immunostained for anti-centromoere antigen (1:100; ACA, Antibodies Inc., Davis, CA, USA), Hec1 (1:1000) and tubulin (1:500). Chromosomes were imaged with Hoechst 33342.
Cell-cycle analysis
A total of 4 Â 10 4 HEK293 cells were grown in 24-well plates for 24 h and then transduced with either rAAV2 shuttle or rAAV2-shHec1(4E) serotype 2 vector (2000 vgparticles per cell (MOI)). Cells were removed with trypsin/EDTA treatment at 70 h post-transduction. Following detachment, PBS (1 ml) was added to the cell solution and the cells were pelleted by centrifugation (5 min at 300 g). The supernatant was removed and the cell pellet was resuspended in 0.3 ml Vindelov's propidium iodide (PI) solution composed of: 1 mM Trizma base, 10 mM NaCl, 5 mg PI, 0.1% (v/v) Nonidet P-40 (NP-40) and 0.70 U/ml RNAse. Cells were incubated in Vindelov's PI solution for at X2 h on ice before cell-cycle 
Giemsa staining U251 cells
Human glioma U251 or HEK293 cells were grown in 24-well plates followed by transduction with either rAAV2-shHec1(4E) or control vector rAAV2 shuttle. Fourteen days (U251) and 7 days (HEK293) after transduction, cell culture 24-well plates were rinsed with PBS and fixed with methanol for 10 min at RT. The plates were air-dried and the cells were stained for 30 min at RT with Giemsa stain modified solution (Fluka Chemie, Switzerland), rinsed with distilled water and dried at RT.
Human tumor cell lines screening for susceptibility to AAV Fifty-six human tumor cell lines derived from nine different organs were used for the screening. AAV1-eGFP, AAV2-eGFP or AAV5-eGFP were transduced 24 h post-seeding the tumor cells. High MOI (MOI based or particles per cell) was used (more than 10 000 infectious virus particles per cell) for all the tumor cell lines. EGFPtransduced cells were observed by fluorescence microscopy and analyzed quantitatively by flow cytometry.
Western-blot analysis for Hec1 depletion
For Figure 6 Western-blot analysis, the cells were lysed in a buffer containing 50 mM Tris-HCl (pH 7.5), 2 mM EDTA, 150 mM NaCl and 1% NP-40. Tumor cells were seeded (1 Â 10 4 cells/well) in 24-well plates 1 day before infection of AAV vectors. Tumor cells (per well) were treated with 1 ml of rAAV-shHec1 vector. The MOI and the period of time used were indicated on the legend of figures. Whole-cell extracts were prepared and analyzed by Western blots for the presence of Hec1 using mouse anti-Hec1 monoclonal antibody (1:2000) (Novus Biologicals, Inc., Littleton, CO, USA) or anti-a-tubulin (1:5000; Sigma-Aldrich Co., St Louis, MO, USA). Goat anti-mouse peroxidase conjugated antibody was used as the secondary antibodies (1:5000; Sigma-Aldrich). The chemiluminescence and X-ray film were used to develop the blots (ECL Advance reagent, Amersham Biosciences, Pittsburgh, PA, USA) according to the manufacturer's instructions. For Figure 3m Western blot, HeLa cells were infected at an MOI of 1000 with either rAAV-shHec1(4E) or shuttle vector 1 day after plating. Forty-eight hours post-infection, whole-cell lysates were harvested in lysis buffer (10 mM Tris (pH 7.5), 200 mM NaCl, 0.1 mM EDTA, 1% Triton X-100 and 1 Â LPC) and immunoblotted for Hec1 (1:1000; 9G3, Abcam Inc., Cambridge, MA, USA) and a-tubulin (1:2000; DM1a, Sigma-Aldrich Co.) as a loading control.
Tumor xenografts in nude mice
All animals used in this paper were housed in the animal care facility at NHLBI following protocols approved by NHLBI/NIH animal care and use committee (NHLBI H-0071 protocol approved 01/2005). Eight-week female Hsd:athymic nude-Foxn1nu mice were used for generating tumor xenograft models and examining rAAVshHec1 vectors antitumor effect. U251 glioma tumor cells (4 Â 10 6 ) suspended in PBS were injected subcutaneously and bilaterally into the flanks of the athymic mice (n ¼ 15). About 1 min of exposure to isoflurane (3%) was used to immobilize the animal. After 1 week, palpable solid tumor formed, then once a week for the next 3 weeks, 20 ml of serotype 1 AAV vectors (1.1 Â 10 9 viral particles and 1.1 Â 10 7 transducing units) were injected intratumorally under anesthesia: rAAV1 shuttle vector (left flank) or rAAV1-shHec1(4E) vector (right flank). Tumor dimensions (length and width) were measured twice a week by digital caliper and the tumor volume was calculated (length Â width 2 /2). Mice were euthanized by CO 2 asphyxiation 3 weeks after the first tumor injection. U251 solid tumor masses were removed from athymic mice. Removed tumor was cut in half and the cut section was used for detection hrGFP expression under the fluorescence stereomicroscope. The tumor tissues were then fixed with 10% buffered formalin, dehydrated, embedded in paraffin and sectioned at a thickness of 5 mm. For diagnostic study, the sections were stained with hematoxylin-eosin and the Masson trichrome.
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